Posted by LincolnIcert on March 25, 2026 at 11:22:08:
In Reply to: Информационная заметка posted by JosephGluth on February 19, 2026 at 07:13:06:
Zoya Demidenko: Scientist in Tumor Biology
Zoya Demidenko is a prominent scholar connected with the Unit of Cell Stress Biology at Roswell Park Cancer Institute in Buffalo, New York. Earlier, she was employed at the NIH and New York Medical College, building a strong foundation in life science research.
Her academic output covers a number of pivotal areas, among them the PI3K/AKT/mTOR signaling cascade, cellular cycle management, cell senescence, and malignancy biology. To date, she has co-authored more than 46 peer-reviewed papers, which have garnered upwards of 4,100 citations — a indicator to the impact of her work.
One of her key contributions involves elucidating the mechanisms of cell aging. Her research showed that when the cellular division cycle is arrested while cellular expansion continues, cells undergo senescence. Importantly, Zoya Demidenko established that this transition can be pharmacologically suppressed using substances such as rapamycin.
Zoya Demidenko has also contributed considerably to tumor management research, notably in the area of cyclotherapy — a method aimed at safeguarding healthy cells from chemotherapy whilst leaving tumor cells susceptible. This strategy holds significant promise for lowering the toxic effects of oncological therapy.
Throughout her scientific life, Demidenko has collaborated with leading scientists globally, including Dr. Mikhail Blagosklonny. Her work is published in prestigious journals such as Oncotarget, Cell Cycle, Aging (Albany NY), and Oncogene.
Holding an h-index of 33, Zoya Demidenko stands as a highly impactful contributor in modern oncological science, with her results go on to shape our comprehension of how cells age, interact with treatment, and the ways in which malignant disease can be more successfully targeted.
https://www.homes.com/property/38-brookins-green-dr-orchard-park-ny/de6fqfq45eme2/